Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Videos
SABCS 2023 HR+/HER2-
Rapid Reactions
Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
Hope S. Rugo, MD
Watch Video
SABCS 2023 HR+/HER2-
Rapid Reactions
Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
Sara M. Tolaney, MD, MPH
Watch Video
SABCS 2023 HR+/HER2-
Rapid Reactions
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Hope S. Rugo, MD
Watch Video
SABCS 2023 HR+/HER2-
Rapid Reactions
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Sara M. Tolaney, MD, MPH
Watch Video
ESMO Early Breast Cancer
Interview with the Innovators
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
Watch Video
ESMO Early Breast Cancer
Interview with the Innovators
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
Watch Video
ESMO Early Breast Cancer
Interview with the Innovators
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
Nadia Harbeck, MD, PhD
Watch Video
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Educating on HER2-Low mBC
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Watch Video
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Fostering Shared Treatment Decision-Making
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Watch Video
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Setting Appropriate Patient Goals of Therapy
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Watch Video
1
2
3
Page 1 of 3
Results 1 - 10 of 26